Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric population, the company announced on Thursday. The trial aims to enroll around 12,000 participants aged 2 to 17,

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., Sanofi has

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair of closely watched trials.

The stock's fall snapped a three-day winning streak.

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet. Read why MRK is a Buy.